About   Help   FAQ
Phenotypes associated with this allele
Allele Symbol
Allele Name
Allele ID 		Mapk14tm2Nbr
targeted mutation 14, Angel R Nebreda
MGI:3715522
Summary 8 genotypes
Jump to Allelic Composition Genetic Background Genotype ID
cn1
 		Mapk14tm2Nbr/Mapk14tm2Nbr
Polr2atm1(cre/ERT2)Bbd/Polr2a+ 		involves: 129 * C57BL/6 * CD-1 * SJL MGI:3716853
cn2
 		Mapk11tm1Jsca/Mapk11+
Mapk14tm2Nbr/Mapk14tm2Nbr
Edil3Tg(Sox2-cre)1Amc/Edil3+ 		involves: 129P2/OlaHsd * C57BL/6 * CBA MGI:5461498
cn3
 		Mapk11tm1Jsca/Mapk11tm1Jsca
Mapk14tm2Nbr/Mapk14tm2Nbr
Edil3Tg(Sox2-cre)1Amc/Edil3+ 		involves: 129P2/OlaHsd * C57BL/6 * CBA MGI:5288510
cn4
 		Mapk11tm1Jsca/Mapk11tm1Jsca
Mapk14tm2Nbr/Mapk14tm3.1(Mapk11)Nbr
Edil3Tg(Sox2-cre)1Amc/Edil3+ 		involves: 129P2/OlaHsd * C57BL/6 * CBA MGI:5288513
cn5
 		Mapk14tm1Nbr/Mapk14tm2Nbr
Polr2atm1(cre/ERT2)Bbd/Polr2a+ 		involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * CD-1 * SJL MGI:3716854
cn6
 		Krastm1Bbd/Kras+
Mapk14tm1Nbr/Mapk14tm2Nbr
Polr2atm1(cre/ERT2)Bbd/Polr2a+ 		involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * CD-1 * SJL MGI:3716855
cn7
 		Krastm1Bbd/Kras+
Mapk14tm2Nbr/Mapk14+
Polr2atm1(cre/ERT2)Bbd/Polr2a+ 		involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * CD-1 * SJL MGI:3716857
cn8
 		Mapk14tm2Nbr/Mapk14tm3.1(Mapk11)Nbr
Edil3Tg(Sox2-cre)1Amc/Edil3+ 		involves: C57BL/6 * CBA MGI:5288515


Genotype
MGI:3716853
cn1
Allelic
Composition		 Mapk14tm2Nbr/Mapk14tm2Nbr
Polr2atm1(cre/ERT2)Bbd/Polr2a+
Genetic
Background		 involves: 129 * C57BL/6 * CD-1 * SJL
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Mapk14tm2Nbr mutation (2 available); any Mapk14 mutation (43 available)
Polr2atm1(cre/ERT2)Bbd mutation (3 available); any Polr2a mutation (92 available)
♀ phenotype observed in females
♂ phenotype observed in males
N normal phenotype
respiratory system
abnormal lung morphology ( J:122397 )
• 2 weeks after 5-hydroxytamoxifen treatment, lungs show increased cellularity
abnormal lung epithelium morphology ( J:122397 )
• lungs show multicellular septa and reduction of the alveolar lumen as early as 2 weeks after 5-hydroxytamoxifen treatment, and is marked after 8 weeks, extending to 60% of the lungs
abnormal pulmonary alveolus epithelial cell morphology ( J:122397 )
• after 5-hydroxytamoxifen treatment, there is an increase in alveolar type II cells compared to controls
• when cultured, isolated progenitor and stem cells (SP-C+, CC-10+ cells) when put under differentiation conditions do not have the capacity to form single positive cells; overexpression of C/EBP alpha in these cells restores the capacity to form SP-C+ cells

cellular
increased cell proliferation ( J:122397 )
• 8 weeks after 5-hydroxytamoxifen treatment, lungs display hyperproliferation (~5-fold increased proliferation) compared to wild-type or heterozygous lungs




Genotype
MGI:5461498
cn2
Allelic
Composition		 Mapk11tm1Jsca/Mapk11+
Mapk14tm2Nbr/Mapk14tm2Nbr
Edil3Tg(Sox2-cre)1Amc/Edil3+
Genetic
Background		 involves: 129P2/OlaHsd * C57BL/6 * CBA
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Edil3Tg(Sox2-cre)1Amc mutation (5 available); any Edil3 mutation (43 available)
Mapk11tm1Jsca mutation (0 available); any Mapk11 mutation (35 available)
Mapk14tm2Nbr mutation (2 available); any Mapk14 mutation (43 available)
♀ phenotype observed in females
♂ phenotype observed in males
N normal phenotype
reproductive system
primary sex reversal ( J:191096 )
• XY sex reversal of gonads at E14.5




Genotype
MGI:5288510
cn3
Allelic
Composition		 Mapk11tm1Jsca/Mapk11tm1Jsca
Mapk14tm2Nbr/Mapk14tm2Nbr
Edil3Tg(Sox2-cre)1Amc/Edil3+
Genetic
Background		 involves: 129P2/OlaHsd * C57BL/6 * CBA
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Edil3Tg(Sox2-cre)1Amc mutation (5 available); any Edil3 mutation (43 available)
Mapk11tm1Jsca mutation (0 available); any Mapk11 mutation (35 available)
Mapk14tm2Nbr mutation (2 available); any Mapk14 mutation (43 available)
♀ phenotype observed in females
♂ phenotype observed in males
N normal phenotype

Developmental defects in Mapk14tm2Nbr/Mapk14tm2Nbr Edil3Tg(Sox2-cre)1Amc/0 Mapk11tm1Jsca/Mapk11tm1Jsca embryos

mortality/aging

nervous system
abnormal neuron proliferation ( J:176023 )
• spina bifida is correlated with neural hyperproliferation
spina bifida ( J:176023 )
• at E13.5
exencephaly ( J:176023 )
• in 30% of mice at E13.5

cardiovascular system
abnormal fetal cardiomyocyte proliferation ( J:176023 )
• decreased proliferation at E13.5

liver/biliary system
abnormal liver morphology ( J:176023 )
• at E13.5 dissociated hepatocytes and infiltration of hematopoietic cells are seen
small liver ( J:176023 )
• at E13.5

reproductive system
primary sex reversal ( J:191096 )
• complete XY sex reversal of gonads at E14.5

muscle
abnormal fetal cardiomyocyte proliferation ( J:176023 )
• decreased proliferation at E13.5

embryo
spina bifida ( J:176023 )
• at E13.5

cellular
abnormal fetal cardiomyocyte proliferation ( J:176023 )
• decreased proliferation at E13.5
abnormal neuron proliferation ( J:176023 )
• spina bifida is correlated with neural hyperproliferation




Genotype
MGI:5288513
cn4
Allelic
Composition		 Mapk11tm1Jsca/Mapk11tm1Jsca
Mapk14tm2Nbr/Mapk14tm3.1(Mapk11)Nbr
Edil3Tg(Sox2-cre)1Amc/Edil3+
Genetic
Background		 involves: 129P2/OlaHsd * C57BL/6 * CBA
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Edil3Tg(Sox2-cre)1Amc mutation (5 available); any Edil3 mutation (43 available)
Mapk11tm1Jsca mutation (0 available); any Mapk11 mutation (35 available)
Mapk14tm2Nbr mutation (2 available); any Mapk14 mutation (43 available)
Mapk14tm3.1(Mapk11)Nbr mutation (0 available); any Mapk14 mutation (43 available)
♀ phenotype observed in females
♂ phenotype observed in males
N normal phenotype

Cardiac defects in Mapk14tm3.1(Mapk11)Nbr/Mapk14tm2Nbr Edil3Tg(Sox2-cre)1Amc/0 Mapk11tm1Jsca/Mapk11tm1Jsca embryos

mortality/aging
postnatal lethality, complete penetrance ( J:176023 )
• present in the expected numbers at E18.5 but none are found at weaning

cardiovascular system

nervous system
nervous system phenotype ( J:176023 )
N
• spina bifida phenotype seen in double null mice is rescued in mice carrying the Mapk14tm3.1(Mapk11)Nbr allele




Genotype
MGI:3716854
cn5
Allelic
Composition		 Mapk14tm1Nbr/Mapk14tm2Nbr
Polr2atm1(cre/ERT2)Bbd/Polr2a+
Genetic
Background		 involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * CD-1 * SJL
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Mapk14tm1Nbr mutation (0 available); any Mapk14 mutation (43 available)
Mapk14tm2Nbr mutation (2 available); any Mapk14 mutation (43 available)
Polr2atm1(cre/ERT2)Bbd mutation (3 available); any Polr2a mutation (92 available)
♀ phenotype observed in females
♂ phenotype observed in males
N normal phenotype
mortality/aging
premature death ( J:122397 )
• mice die before week 32 due to increased lung cancer progression

respiratory system
enlarged lung ( J:122397 )
• 20 weeks after treatment, lungs are increased in size
increased lung tumor incidence ( J:122397 )
• 2 weeks after 5-hydroxytamoxifen treatment, small tumors are found in the lungs
• 20 weeks after treatment, lungs are oversized with 2-3 times as many tumors, many often >2mm in diameter, while lungs of Kras, Mapk14 heterozygotes have normal lungs with fewer, smaller tumors; tumors in Mapk14 homozygotes are more poorly differentiated and have higher mitotic indices
• at 26 weeks, total tumor number is slightly higher than in controls with much higher numbers of tumors larger than 2 mm in diameter and a higher ratio of lung mass to total mass
increased lung adenoma incidence ( J:122397 )
• tumors are detected 2 weeks after 5-hydroxytamoxifen treatment and after 4 weeks, clear signs of adenomas are present in most lungs compared to only a few small adenomas in lungs of treated Kras, Mapk14tm2Nbr/+ control mice
increased lung adenocarcinoma incidence ( J:122397 )
• adenocarcinomas are detected at 15 weeks but not in controls
abnormal lung development ( J:122397 )
• lung differentiation is abnormal with increased SP-C-positive cells

neoplasm
abnormal tumor incidence ( J:122397 )
• mice also have tumors in the thymus and organs such as kidney and liver by 24 weeks after treatment whereas controls only have tumors in lungs and thymus
increased lung tumor incidence ( J:122397 )
• 2 weeks after 5-hydroxytamoxifen treatment, small tumors are found in the lungs
• 20 weeks after treatment, lungs are oversized with 2-3 times as many tumors, many often >2mm in diameter, while lungs of Kras, Mapk14 heterozygotes have normal lungs with fewer, smaller tumors; tumors in Mapk14 homozygotes are more poorly differentiated and have higher mitotic indices
• at 26 weeks, total tumor number is slightly higher than in controls with much higher numbers of tumors larger than 2 mm in diameter and a higher ratio of lung mass to total mass
increased lung adenoma incidence ( J:122397 )
• tumors are detected 2 weeks after 5-hydroxytamoxifen treatment and after 4 weeks, clear signs of adenomas are present in most lungs compared to only a few small adenomas in lungs of treated Kras, Mapk14tm2Nbr/+ control mice
increased lung adenocarcinoma incidence ( J:122397 )
• adenocarcinomas are detected at 15 weeks but not in controls

growth/size/body
enlarged lung ( J:122397 )
• 20 weeks after treatment, lungs are increased in size




Genotype
MGI:3716855
cn6
Allelic
Composition		 Krastm1Bbd/Kras+
Mapk14tm1Nbr/Mapk14tm2Nbr
Polr2atm1(cre/ERT2)Bbd/Polr2a+
Genetic
Background		 involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * CD-1 * SJL
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Krastm1Bbd mutation (2 available); any Kras mutation (84 available)
Mapk14tm1Nbr mutation (0 available); any Mapk14 mutation (43 available)
Mapk14tm2Nbr mutation (2 available); any Mapk14 mutation (43 available)
Polr2atm1(cre/ERT2)Bbd mutation (3 available); any Polr2a mutation (92 available)
♀ phenotype observed in females
♂ phenotype observed in males
N normal phenotype
mortality/aging
premature death ( J:122397 )
• mice die before week 32 due to increased lung cancer progression

respiratory system
enlarged lung ( J:122397 )
• 20 weeks after treatment, lungs are increased in size
increased lung tumor incidence ( J:122397 )
• 2 weeks after 5-hydroxytamoxifen treatment, small tumors are found in the lungs
• 20 weeks after treatment, lungs are oversized with 2-3 times as many tumors, many often >2mm in diameter, while lungs of Kras, Mapk14 heterozygotes have normal lungs with fewer, smaller tumors; tumors in Mapk14 homozygotes are more poorly differentiated and have higher mitotic indices
• at 26 weeks, total tumor number is slightly higher than in controls with much higher numbers of tumors larger than 2 mm in diameter and a higher ratio of lung mass to total mass
increased lung adenoma incidence ( J:122397 )
• tumors are detected 2 weeks after 5-hydroxytamoxifen treatment and after 4 weeks, clear signs of adenomas are present in most lungs compared to only a few small adenomas in lungs of treated Kras, Mapk14tm2Nbr/+ control mice
increased lung adenocarcinoma incidence ( J:122397 )
• adenocarcinomas are detected at 15 weeks but not in controls
abnormal lung development ( J:122397 )
• lung differentiation is abnormal with increased SP-C-positive cells

neoplasm
abnormal tumor incidence ( J:122397 )
• mice also have tumors in the thymus and organs such as kidney and liver by 24 weeks after treatment whereas controls only have tumors in lungs and thymus
increased lung tumor incidence ( J:122397 )
• 2 weeks after 5-hydroxytamoxifen treatment, small tumors are found in the lungs
• 20 weeks after treatment, lungs are oversized with 2-3 times as many tumors, many often >2mm in diameter, while lungs of Kras, Mapk14 heterozygotes have normal lungs with fewer, smaller tumors; tumors in Mapk14 homozygotes are more poorly differentiated and have higher mitotic indices
• at 26 weeks, total tumor number is slightly higher than in controls with much higher numbers of tumors larger than 2 mm in diameter and a higher ratio of lung mass to total mass
increased lung adenoma incidence ( J:122397 )
• tumors are detected 2 weeks after 5-hydroxytamoxifen treatment and after 4 weeks, clear signs of adenomas are present in most lungs compared to only a few small adenomas in lungs of treated Kras, Mapk14tm2Nbr/+ control mice
increased lung adenocarcinoma incidence ( J:122397 )
• adenocarcinomas are detected at 15 weeks but not in controls

growth/size/body
enlarged lung ( J:122397 )
• 20 weeks after treatment, lungs are increased in size




Genotype
MGI:3716857
cn7
Allelic
Composition		 Krastm1Bbd/Kras+
Mapk14tm2Nbr/Mapk14+
Polr2atm1(cre/ERT2)Bbd/Polr2a+
Genetic
Background		 involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * CD-1 * SJL
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Krastm1Bbd mutation (2 available); any Kras mutation (84 available)
Mapk14tm2Nbr mutation (2 available); any Mapk14 mutation (43 available)
Polr2atm1(cre/ERT2)Bbd mutation (3 available); any Polr2a mutation (92 available)
♀ phenotype observed in females
♂ phenotype observed in males
N normal phenotype
mortality/aging
premature death ( J:122397 )
• mice live up to 40 weeks

neoplasm
increased hemolymphoid system tumor incidence ( J:122397 )
• by 24 weeks, mice develop tumors in the thymus
increased lung tumor incidence ( J:122397 )
• by 24 weeks, mice develop tumors in lungs
increased lung adenoma incidence ( J:122397 )
• at 4 weeks after 5-hydroxytamoxifen treatment, a few small adenomas are observed in some animals

respiratory system
increased lung tumor incidence ( J:122397 )
• by 24 weeks, mice develop tumors in lungs
increased lung adenoma incidence ( J:122397 )
• at 4 weeks after 5-hydroxytamoxifen treatment, a few small adenomas are observed in some animals




Genotype
MGI:5288515
cn8
Allelic
Composition		 Mapk14tm2Nbr/Mapk14tm3.1(Mapk11)Nbr
Edil3Tg(Sox2-cre)1Amc/Edil3+
Genetic
Background		 involves: C57BL/6 * CBA
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Edil3Tg(Sox2-cre)1Amc mutation (5 available); any Edil3 mutation (43 available)
Mapk14tm2Nbr mutation (2 available); any Mapk14 mutation (43 available)
Mapk14tm3.1(Mapk11)Nbr mutation (0 available); any Mapk14 mutation (43 available)
♀ phenotype observed in females
♂ phenotype observed in males
N normal phenotype
mortality/aging
postnatal lethality, incomplete penetrance ( J:176023 )
• about 30% of mice survive to adulthood




Contributing Projects:
Mouse Genome Database (MGD), Gene Expression Database (GXD), Mouse Models of Human Cancer database (MMHCdb) (formerly Mouse Tumor Biology (MTB)), Gene Ontology (GO)
Citing These Resources
Funding Information
Warranty Disclaimer, Privacy Notice, Licensing, & Copyright
Send questions and comments to User Support. 		last database update
11/12/2024
MGI 6.24 		The Jackson Laboratory